Article
Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
Cancer chemotherapy and pharmacology - 1 Jan 2012
Joerger M, Burgers J A, Baas P, Doodeman V D, Smits P H M, Jansen R S, Vainchtein L D, Rosing H, Huitema A D R, Beijnen J H, Schellens J H M
Abstract excerpt
BACKGROUND: This study quantified the impact of drug pathway-associated genetic variants on the pharmacokinetics (PK) of gemcitabine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC). METHODS: Thirty-seven patients with advanced NSCLC were sampled for plasma concentrations of gemcitabine, difluoro-deoxy uridine (dFdU), intracellular gemcitabine triphosphates (dFdCTP), and unbound platinum...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.